Notícias e Atividades da Agios Pharmaceuticals

Agios Pharmaceuticals pertence à Sagard Holdings. Sagard Holdings tem presença direta em 4 países.

Sagard Holdings possui 12 subsidiárias incluindo Acheel, Achieve e ADIT.

Eles estão dentro:

• Seguros23%
• Serviços Financeiros23%
• Outro54%

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Agios Pharmaceuticals

• Brian Goff, Chief Executive Officer and Director
• Jacqualyn Fouse, Chairman of the Board
• Maykin Ho, Director

Recentes movimentos de executivos em Agios Pharmaceuticals

• Krishnan Viswanadhan, ingressou na Companhia como Chief Corporate Development & Strategy Officer  (Notícia publicada em 7 de março de 2025).
• David Schenkein, Director, deixará a Companhia em 28 de fev. de 2025  (Notícia publicada em 14 de fevereiro de 2025).

Recentes movimentos de executivos em Sagard Holdings

• Parinaz Sobhani, ingressou na Companhia como Head, Artificial Intelligence  (Notícia publicada em 30 de agosto de 2024).

Criar um alerta
para seguir os movimentos de executivos da Agios Pharmaceuticals.

Sagard Holdings possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Agios Pharmaceuticals

• Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 | Agios Pharmaceuticals, Inc.
• Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia | Agios Pharmaceuticals, Inc.
• Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients | Agios Pharmaceuticals, Inc.
• Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs | Agios Pharmaceuticals, Inc.
• Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 | Agios Pharmaceuticals, Inc.
• Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 | Agios Pharmaceuticals, Inc.
• Agios Reports Business Highlights and Second Quarter 2020 Financial Results | Agios Pharmaceuticals, Inc.
• Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020 | Agios Pharmaceuticals, Inc.
• Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 | Agios Pharmaceuticals, Inc.
• Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia | Agios Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Agios Pharmaceuticals

• Agios Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Agios Pharmaceuticals na LinkedIn, Twitter e YouTube